Emerging BioTalk
  • Home
  • About Us
  • Contact
  • Search
  • Menu

China’s Emerging Biotech and CDMO Environment

December 2, 2020/in Bioprocessing, End-to-End Solutions, News /by Vicky (Qing) Xia

China is going through a phase of robust growth of biotech companies. This is being boosted by market demand, returning scientists-turned innovators and a favorable capital market, according to BioPlan’s Advances in Biopharmaceutical Technology in China, 2nd ed1. This is especially the case in the Science and Technology Innovation Board in China (STAR) and the Hong Kong Stock Market.

As we note below, the markets for contract bioprocessing are clearly on the rise, and investors, both domestic and international, have seen China’s biologics CDMO landscape as a new growth opportunity. Boehringer-Ingelheim is the first international biologics CDMO to test the waters in China, and the key mover and shaker behinds China’s MAH reform, which opens the door for commercial scale contract bioprocessing.

Lonza,

Merck
MilliporeSigma
, Celltrion, etc., have all followed suit, according to Growth of Biopharmaceutical Contract Organizations in China3 from BioPlan. Emerging biotech companies in China now have plenty of China-based CDMOs to choose from; this information can help them make strategic choices.

Growth in China’s Biologics Markets

Rapid urbanization, greater accessibility to the national healthcare insurance program, and an aging population has created significant market demands for biopharmaceuticals, which used to be regarded as luxury drugs only available to the wealthy.

Figure 1 China Biologics Market Size Projection

China’s capital markets are also getting more and more interested in biotech and the biopharma industry. The STAR market gives high evaluations (35% above average P/E ratio of all companies listed on it) to life science and healthcare companies,. This is the highest among all sectors including IT, telecommunication, materials and manufacturing, etc.

The exit route via IPO has also encouraged venture capitalists to enter the biotech sector, so much so that hardly a week passes without news about biotech companies successfully raising funds in Series A, B, or pre-IPO rounds. One noteworthy key move is that the STAR market and HK stock market no longer require biotech companies to have marketed products to get listed (STAR market requires biotech companies to have a phase II  pipeline for IPO2), which means that capital markets realize the value of pipelines.

For start-up biotech companies, CDMOs have become a must. As innovators with no marketed products, start-up companies have to focus on their key strength, i.e. research and development of the pipeline. They can’t afford to spend the time or their limited financial resources on bioprocessing facilities, which can cost hundreds of millions of RMB or even higher. Worse, the time required to commission a facility would delay the launch of a new biologic by years.

In our June 2020 study, we found a number of domestic biologics CDMOs have been founded between 2018-2020, though the market currently is dominated by one single player, WuXi Biologics. With over a hundred mAb projects currently at clinical stage, and dozens more getting IND from NMPA annually, industry insiders expect China to see ~10 BLA approved each year in the near future, which could translate to an additional 100k liter capacity in demand with a significant portion of it from biologics CDMOs3. The growth of CDMOs also brings market opportunities for single-use supply vendors, as more CDMOs prefer single use systems.

While start-up biotech companies need to partner with CDMOs to speed up the development of their pipeline to IND stage, once their products start clinical trials, many developers will seek funds to build up their own in-house facilities.

References

  1. Advances in Biopharmaceutical Technology in China, 2nd ed., BioPlan Associates, Inc., and Society for Industrial Microbiology and Biotechnology (SIMB), Oct 2018.
  2. Yangge, Zhao, Loss-making Zejing Biotechnology Innovation Board IPO has passed: the product has not been sold, and it may not be profitable in the next few years”, Sina Finance, October 31, 2019.
  3. Growth of Biopharmaceutical Contract Organizations in China, BioPlan Associates, Inc. June, 2020
  • Author
  • Recent Posts
Vicky (Qing) Xia
Senior Project Director at BioPlan Associates
Vicky (Qing) XIA is the senior project director at BioPlan Associates. She has an MS in biology from University of Texas-Houston, and an MBA from the University of Pittsburgh, she has experience in consulting, business development, as well as alliance management in China’s biopharmaceutical industry.Her expertise includes developing research and analysis on multiple global market segments, and she has managed a team of industry experts, and projects. vxia@bioplanassociates.com, +1 301-921-5979, www.bioplanassociates.com
Latest posts by Vicky (Qing) Xia (see all)
  • China’s Emerging Biotech and CDMO Environment - December 2, 2020

 

0
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share by Mail
http://emergingbiotalk.com/wp-content/uploads/2020/12/China-mAb-market.jpg 316 553 Vicky (Qing) Xia http://emergingbiotalk.com/wp-content/uploads/2020/05/emergingbiotalk-header.png Vicky (Qing) Xia2020-12-02 14:35:062021-04-13 02:58:08China’s Emerging Biotech and CDMO Environment

Biotech Resource Hub >>

  • SUBSCRIBE TO OUR BLOG
  • SUBMIT YOUR BLOG POST

Latest News

  • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
  • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
  • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

Categories

  • Bioprocessing
  • Biosafety Testing
  • End-to-End Solutions
  • Frontpage Article
  • Gene Therapy
  • Investigator's Brochure
  • News
  • Uncategorized
  • Vaccines
  • Viral Vectors
  • Webinar

Archives

  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • May 2020
  • April 2020
  • SUBSCRIBE TO OUR BLOG
  • SUBMIT YOUR BLOG POST

Latest News

  • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
  • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
  • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

Categories

  • Bioprocessing
  • Biosafety Testing
  • End-to-End Solutions
  • Frontpage Article
  • Gene Therapy
  • Investigator's Brochure
  • News
  • Uncategorized
  • Vaccines
  • Viral Vectors
  • Webinar

Archives

  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • May 2020
  • April 2020

Tags

applications bioprocessing biotech blazar Congratulations Content education Europe FDA Format gene therapy grant grants Investigator's Brochure molecule new NGS Pharmaceuticals program services symposia tags things Tone VAR2 viral assurance viral clearance virus virus detection winner

Business Hours

Our support Hotline is available 24 Hours a day: (555) 343 456 7891

  • Monday-Friday: 9am to 5pm
  • Saturday: 10am to 2pm
  • Sunday: Closed

Latest News

  • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
  • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
  • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am
  • The Future of BiopharmaDecember 6, 2022 - 4:39 am
  • Last chance: 3rd Annual Startup Symposium – Day 3November 10, 2022 - 5:39 am
  • The Lack of Funding for Women Entrepreneurs Doesn’t Stop Them from Launching – But We Still Have a Long Way to Go – And We Can Help Each Other. Assurea is ROOTING FOR YOU!October 21, 2022 - 8:27 am

Categories

  • Bioprocessing
  • Biosafety Testing
  • End-to-End Solutions
  • Frontpage Article
  • Gene Therapy
  • Investigator's Brochure
  • News
  • Uncategorized
  • Vaccines
  • Viral Vectors
  • Webinar
  • Author
  • Recent Posts
Vicky (Qing) Xia
Senior Project Director at BioPlan Associates
Vicky (Qing) XIA is the senior project director at BioPlan Associates. She has an MS in biology from University of Texas-Houston, and an MBA from the University of Pittsburgh, she has experience in consulting, business development, as well as alliance management in China’s biopharmaceutical industry.Her expertise includes developing research and analysis on multiple global market segments, and she has managed a team of industry experts, and projects. vxia@bioplanassociates.com, +1 301-921-5979, www.bioplanassociates.com
Latest posts by Vicky (Qing) Xia (see all)
  • China’s Emerging Biotech and CDMO Environment - December 2, 2020
0
© 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. | Privacy Policy | Cookie Settings
Investment in Internal Process Development and Manufacturing Enables Rapid Product... Lab space in Germany for emerging Biotechs expected to open in 2021
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. We use cookies in our website to give you the most relevant experience. By clicking or navigating the site, you are accepting the use of all our cookies according to our Cookie Policy / Privacy Statement. You are free to decide in the Cookie Settings which categories you would like to allow. Please note that depending on what you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy

Accept All CookiesCookie Settings

Cookie and Privacy Settings



Cookie Preferences

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about how we use and share your data, please follow this link.
Privacy Statement

Necessary

Always Active
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.

Functional

These cookies enable the provision of advanced functionalities and are used for personalization. The cookies are set in particular in response to your actions and depend on your specific service requests (e.g., pop-up notification choices).Changes will take effect once you reload the page.

Targeting

These cookies may be set to learn more about your interests and show you relevant ads on other websites. These cookies work by uniquely identifying your browser and device. By integrating these cookies, we aim to learn more about your interests and your surfing behavior and to be able to place our advertising in a targeted manner.

Confirm My ChoicesAllow AllDisable All

loading

Please wait while you are redirected to the right page...

Please share your location to continue.

Check our help guide for more info.

share your location